Tortoise Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Tortoise Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9	Closed	-$4.1K	–	287
2025 Q3	$4.1K	Buy	9 +3	+50%	+$1.22K	﹤0.01%	730
2025 Q2	$1.96K	Buy	+6	New	+$1.66K	﹤0.01%	807
2018 Q3	–	Sell	-198	Closed	-$20K	–	550
2018 Q2	$20K	Hold	198	–	–	0.01%	333
2018 Q1	$24K	Hold	198	–	–	0.01%	304
2017 Q4	$25K	Hold	198	–	–	0.01%	301
2017 Q3	$23K	Hold	198	–	–	0.01%	288
2017 Q2	$16K	Buy	+198	New	+$12.7K	0.01%	303

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Tortoise Investment Management's ALNY Position: Q4 2025 in Review

Tortoise Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 9 shares — an estimated $4.1K sold.

Tortoise Investment Management first reported a position in ALNY in Q2 2017 and held it in 7 quarters. The position peaked at $25K in Q4 2017. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

Tortoise Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Tortoise Investment Management sold 9 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $4.1K.
Tortoise Investment Management first reported a position in Alnylam Pharmaceuticals in Q2 2017 and held it in 7 quarters.
Tortoise Investment Management's Alnylam Pharmaceuticals position peaked at $25K in Q4 2017.
851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Tortoise Investment Management's 13F filing for Q4 2025, filed 6 Feb 2026.